The study of the effects of serotonin (5-hydroxytrypta-mine [5-HT]) on intestinal secretions and motility has been given new impetus by the imminent launch of a number of 5-HT-modulating drugs for the treatment of functional bowel disorders [1,2]. These new drugs are described later in this issue by Silvia Delgado Aros, MD, and Michael Camilleri, MD (pp 140-146). Gastro-enterologists now need to have a working knowledge of 5-HT pharmacology to understand the various claims and counterclaims made about these new products.
展开▼
